How to verify AOD9604 (Fragment 176-191) purity and batch documentation
A laboratory-focused guide to verifying AOD9604 (Fragment 176-191) identity, purity and batch documentation, with the analytical and regulatory context the published evidence supports.
AOD9604, also written AOD-9604 and described in the literature as the hGH fragment 176-191 or Anti-Obesity Drug 9604, is a synthetic peptide fragment corresponding to the C-terminal region of human growth hormone. It is classified among the peptides marketed as research compounds intended to modulate the growth hormone–insulin-like growth factor-1 (GH-IGF-1) axis, and it appears in the same regulatory category as GHRH analogues and growth hormone secretagogues in reviews of performance-enhancing peptides sold online [1]. The published evidence available to this page does not supply a sequence, molecular formula or molecular weight for the fragment, so no such values are stated here; identity verification therefore rests on the certificate of analysis supplied with a given lot rather than on figures reproduced from these sources.
The work indexed here centres on the GH-IGF-1 axis and on peptide-mediated modulation of signalling networks relevant to tissue regeneration, including PI3K/Akt, mTOR, MAPK, TGF-β and AMPK [6].
Research Studies
AOD9604 and its position among GH-IGF-1 axis peptides
Reviews of performance-enhancing peptides encountered in clinical practice and in online self-administration protocols group AOD9604 (hGH 176-191) with GHRH analogues such as sermorelin, tesamorelin and the CJC-1295 variants, and with growth hormone secretagogues including GHRP-2, GHRP-6, hexarelin and ipamorelin [1]. The same literature notes that these agents are marketed as “research compounds” while remaining unregulated, which is the context in which batch documentation questions arise [1].
AOD9604 and the gray-market peptide category
A review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance describes peptides as short amino acid chains occupying a pharmacological niche between small-molecule drugs and large proteins, and identifies a parallel gray market of unapproved compounds operating largely outside regulatory oversight [2][3]. AOD-9604 (Anti-Obesity Drug 9604) is named among the peptides marketed direct to patients in that review [2][3]. The same review states that numerous peptide drugs have undergone a rigorous approval process evaluating safety and efficacy, in contrast to the unapproved category [2][3].
AOD9604 and the documentation gap in unapproved peptides
Because the gray market operates outside regulatory oversight [2][3], the analytical record for a given lot is generated by the supplier rather than by a regulator. The evidence block for this page does not contain a study reporting measured purity values for AOD9604 lots, so no purity figures are quoted here. What the sources do establish is the category: unapproved peptides marketed direct to patients, with AOD-9604 named among them [2][3].
AOD9604 and detection methods for small peptides in blood matrices
Analytical workflows for small peptides have been developed for anti-doping purposes. One study reports a fast, streamlined and harmonized procedure capable of detecting 54 prohibited substances in dried and liquid blood matrices, developed in response to earlier dried-blood-spot methods that required multiple sample preparation steps and were labour-intensive and costly [4]. That work concerns detection of peptidic and non-peptidic doping agents rather than supplier purity testing, and it is cited here only to indicate the analytical state of the art for small peptides in biological matrices [4].
AOD9604 and peptide signalling pathways in orthopaedic research
A review of therapeutic peptides in orthopaedics describes peptides as emerging adjuncts grounded in their ability to modulate molecular signalling networks central to cellular medicine, acting on pathways including PI3K/Akt, mTOR, MAPK, TGF-β and AMPK, with influence over tissue regeneration [6]. This is a general statement about therapeutic peptides as a class and is not specific to AOD9604; it is included because it defines the pathway families against which fragment work is typically discussed [6].
AOD9604 and the limits of the available evidence
The sources indexed for this page are reviews and analytical-methods papers. They do not report controlled human trials of AOD9604, and they do not report animal or in vitro potency data for the fragment. Any statement that the fragment produces a given effect in a given model is therefore outside what this evidence block supports, and none is made here. Where a claim cannot be traced to [1] through [6], it has been left out.
AOD9604 and what a batch record should let a laboratory check
Given the absence of published identity constants in these sources, verification is a documentary exercise. The table below sets out the categories a laboratory can check against a supplier’s certificate of analysis, alongside the status of that category in the evidence indexed here.
| Verification item | What the laboratory checks | Status in indexed evidence |
|---|---|---|
| Compound identity | Formal name and synonyms on the label match the record | Named as AOD9604 (hGH 176-191) and AOD-9604 (Anti-Obesity Drug 9604) [1][2][3] |
| Sequence, formula, molecular weight | Values stated on the certificate | Not supplied by the indexed sources |
| Purity value | Chromatographic purity figure for the lot | No measured values reported in the indexed sources |
| Regulatory status | Whether the material is an approved or unapproved peptide | Placed in the unapproved, gray-market category [2][3] |
| Analytical method precedent | Whether small-peptide detection methods exist for biological matrices | Harmonized workflow for 54 prohibited substances reported [4] |
AOD9604 and the regulatory classification that shapes documentation
The distinction drawn in the literature is between peptide drugs that have completed a rigorous approval process evaluating safety and efficacy and unapproved compounds marketed outside regulatory oversight [2][3]. AOD-9604 sits in the second group [2][3]. For a laboratory, that classification is the reason batch documentation is requested directly from the supplier: there is no regulatory dossier to consult. The same review literature notes that patient demand for accelerated recovery and performance enhancement is driving expansion of peptide use in sports medicine, which is the commercial pressure behind the gray market [2][3].
AOD9604 and the GH-IGF-1 axis framing
The GH-IGF-1 axis is the framework in which AOD9604 is discussed alongside GHRH analogues and growth hormone secretagogues [1]. That framing describes where the compound is placed in the literature, not what it does; the indexed sources do not report axis-level outcomes for the fragment itself [1].
If you are reading this for personal health reasons
This material is sold for laboratory research only, and we do not provide dosing or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician. Nothing on this page is a recommendation for human use.
Sources
- [1] The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration — https://europepmc.org/article/PMC/PMC13322892
- [2] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://doi.org/10.20944/preprints202512.1011.v3
- [3] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://doi.org/10.20944/preprints202512.1011.v1
- [4] Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices — https://pubmed.ncbi.nlm.nih.gov/42328738/
- [5] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://pubmed.ncbi.nlm.nih.gov/41966639/
- [6] Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — https://europepmc.org/article/PMC/PMC12753158